Floatz logo

ABATACEPT RECOMBINANT

Wiskott-Aldrich Syndrome

Emory Universityprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Wiskott-Aldrich Syndrome cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Roswell Park Cancer Institute
Phase 2BB
Evomela
Washington University School of Medicine
Phase 2BB
TACROLIMUS
Roswell Park Cancer Institute
Phase 2BB
Fludarabine
Roswell Park Cancer Institute
Phase 2BB
Thiotepa
University of Florida
Phase 2BB

View all 16 →

Same molecule, other indications

ABATACEPT RECOMBINANT is also rated in:

Primary Biliary CholangitisDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →